NCT01737255|Completed
Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome
SIGNIFY
Loading search results
SIGNIFY
Sponsor study identifier
observational
88
1 country
1
Study Start
October 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2016
Actual (reported)Study Completion
December 2017
Actual (reported)This study is aimed at exploring the use of whole body MRI for early cancer detection in TP53 mutation carriers and population controls, with the hypothesis that more cancers will be detected in the TP53 mutation carrier group. A secondary end-point will be the number of incidental findings detected and subsequent investigations required. A series of questionnaires will be used to assess the psychological impact of screening on both the study and control group.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2012
Date type not reportedThis date has not been verified as actual or estimated.
November 27, 2012
Actual (reported)November 29, 2012
Actual (reported)September 2016
Actual (reported)December 2017
Actual (reported)Diagnosis of malignant disease
Following MRI scan further investigations may be required to diagnose malignancy
Within 12 months of MRI scan
Diagnosis of relevant non-malignant disease
12 months following MRI scan
Diagnosis of non-relevant disease, number and type of investigations required
12 months following MRI
Psychological impact of MRI screening
12 months following MRI screening
Carriers of TP53 mutation not known to be low penetrance
Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years
Individuals will undergo whole body and brain MRI
All recruits will complete questionnaires at 6 time points to assess psychological impact
The TP53 mutation carriers will be recruited from genetics clinics and through advertising. The population controls will be recruited through advertising
Cancer Genetics Unit, Royal Marsden Hospital
Sutton, Surrey, SM2 5PT, United Kingdom
Rosalind Eeles, PhD
Institute of Cancer Research, Surrey, UK
88 participants (actual enrollment reported by the registry).
First Submitted
November 27, 2012
First Posted
November 29, 2012
Study Start
October 2012
Date type not reportedThis date has not been verified as actual or estimated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
September 2016
Actual (reported)Study Completion
December 2017
Actual (reported)Last Updated
March 31, 2022
Record last verified: 2022-03
Anonymised data can be applied for via the Steering Committee
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: